See accompanying complete Prescribing Information for TESTOPEL.

Transcription

1 See accompanying complete Prescribing Information for.

2 Testopel Means... No Pain, All Gain Month 1 Month 2 Month 3 Month 4 Months 5 or 6 Week Testosterone Injection Into Muscle 3-6 Pellets placed under the skin in back of hip Bi-weekly Testosterone Injection Into Muscle eliminates potential obstacles to patient compliance, such as the need for self-injection training, painful intramuscular injections and a dosing schedule that may be difficult to follow. Testosterone pellets are the androgen formulation with the longest biological action and strongest pharmacodynamic efficacy. 1

3 Treatment Considerations Compliance Convenience Cost* PATIENT: THE BUSY PROFESSIONAL Name: Tom Age: 48 Profession: Manufacturing Executive Insurance: Premium Plan With National Carrier Lifestyle: Professional travel 3x per month, personal travel 2-4x per year, exercises at gym 2-3 weekday mornings per week TREATMENT SELECTION T GEL OR? Frequent travel may interrupt patient compliance. Patient may not want to apply T gel at gym 2-3 mornings per week. T GEL Daily application post-shower Monthly trip to pharmacy for refill 4x per year office visit Medication co-pay - $600 per year Office visit co-pay - $80 per year TOTAL - $680 per year Placement 2-3x per year 4x per year office visit 100% covered under medical benefits Office visit co-pay - $80 per year TOTAL - $80 per year Recommendation: Scheduling issues may risk compliance with T gel. Insurance covers 100% of. Recommend pellets. SAVE $600/yr.* * Assumptions Testosterone Gel: $50 per month pharmacy co-pay; pellets: pellet placement covered at 100% under medical benefits. For either therapy each office visit is a $20 co-pay. ONLY IMPLANTABLE TESTOSTERONE PELLETS PRODUCE SERUM T LEVELS WITHIN NORMAL RANGE FOR UP TO 6 MONTHS 1 Testosterone (nmol/l)* Lower Limit of Normal 300 ng/dl Time (days) *nmol/l multiplied by 30 yields ng/dl By day 2 post-pellet insertion, all patients had reached a serum T level plateau. 1 Testosterone levels remained above the lower limit of normal (10 nmol/l) for ~6 months. 1 Author s Conclusion: T-pellets are the androgen formulation with the longest biological action and strongest pharmacodynamic efficacy in terms of gonadotrophin suppression. The pharmacokinetic features are advantageous compared to other T preparations, and the patient acceptance is high. IMPORTANT SAFETY INFORMATION may produce the following adverse events: breast development and breast discomfort, extra fluid in the body (edema), prostate enlargement accompanied by difficulty in urinating and changes in cholesterol blood levels. Men with carcinomas of the breast or with known or suspected carcinomas of the prostate should not take Pregnant women should also not take. LESS THAN 50% OF PATIENTS REMAIN COMPLIANT WITH THEIR MEDICATION 2 100% 80% 60% 40% 20% 0% 76% Rx Taken 9 OF 10 MEN PREFER T-PELLETS OVER THEIR PREVIOUS TREATMENT MODALITY 3 47% Rx Continued is the only FDA-approved testosterone replacement therapy that delivers spontaneous daily compliance, ensuring patients get the medicine they need so the desired clinical benefits are realized. PATIENT: THE PRE-DIABETIC TEACHER WITH CAPPED PHARMACY BENEFITS Name: Rick Age: 56 Profession: High School Teacher Insurance: Capped Pharmacy Benefit Plan Considerations: Pre-diabetic Treatment Considerations Compliance Convenience Cost* TREATMENT SELECTION T GEL OR? Recommendation: Patient is pre-diabetic; therefore, compliance with testosterone replacement therapy and lifestyle modification is critical. T GEL Daily application post-shower Monthly trip to pharmacy for refill 6x per year office visit Medication co-pay - $600 per year Medication expense post-pharmacy benefit limit - $800 per year Office visit co-pay - $240 per year TOTAL - $1,640 per year Placement 2-3x per year 6x per year office visit Medication - $540 per year Pellet placement - $150 per year Office visit co-pay - $240 per year TOTAL - $930 per year Compliance is essential for pre-diabetic. Patient s insurance benefits make an excellent choice. Recommend pellets. SAVE OVER $700/yr.* * Assumptions Testosterone Gel: $75 per month pharmacy co-pay for 8 months and $200 per month post-pharmacy benefit; : 6 pellets, 3x per year, $30 per pellet to patient, balance of pellet expense covered under medical benefits, pellet placement covered at 50%. For either therapy each office visit is a $40 co-pay.

4 Testopel Means... No Mess, Less Distress Avoid Daily Application of Medication Avoid Monthly Co-pays Avoid Monthly Trips to the Pharmacy Avoid the Worry of Transferring Medication to Women/Children Avoid Daily Interference with Showers and Workouts YES YES YES YES YES Gel Therapy NO NO NO NO NO eliminates potential obstacles to patient compliance, such as the daily administration of gel therapy and high pharmacy co-pays.

5 THE REIMBURSEMENT PROGRAM ONE SIMPLE CALL DOES IT ALL. ONE SIMPLE CALL... AND YOUR REIMBURSEMENT PROGRAM TEAM GOES TO WORK A small, knowledgeable team will be assigned to your practice. - Your Reimbursement Team will routinely communicate with the insurance plans that represent your patient population. ONE SIMPLE CALL... AND YOUR REIMBURSEMENT PROGRAM TEAM DOES ALL THE HEAVY LIFTING Pre-Treatment Services 4 Benefit Investigation 4 Prior Authorization Post-Treatment Services 4 Claim Appeal 4 Low Payment Appeal p: 866.SLATE.50, opt. 5 f: Monday Friday, 9:00am 6:00pm ET IMPORTANT SAFETY INFORMATION SLATE PHARMACEUTICALS HEADQUARTERS 318 Blackwell Street, Suite 240 Durham, North Carolina p: 866.SLATE.50 f: REIMBURSEMENT PROGRAM p: 866.SLATE.50, opt. 5 f: Monday Friday, 9:00am 6:00pm ET may produce the following adverse events: breast development and breast discomfort, extra fluid in the body (edema), prostate enlargement accompanied by difficulty in urinating and changes in cholesterol blood levels. Men with carcinomas of the breast or with known or suspected carcinomas of the prostate should not take. Pregnant women should also not take. References: 1. Jockenhövel F, Vogel E, Kreutzer M, Reinhardt W, Lederbogen S, Reinwein D. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol. 1996;45(1): Disease Management and Drug Adherence DMHC2303. Datamonitor (06/2007). 3. Handelsman DJ, Mackey MA. Howe C, Turner L, Conway AJ. Am analysis of testosterone implants for androgen replacement therapy. Clin Endo. 1997;47: Slate Pharmaceuticals. All rights reserved. Printed in the USA. Testopel 35748